参考文献/References:
［1］ SEHN L H,HERRERA A F,FLOWERS C R,et al.Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma［J］.J Clin Oncol,2019:O1900172.
［2］ REN W,YE X,SU H,et al.Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma［J］.Blood,2018,131(24):2670-2681.
［3］ HE Y,LI J,DING N,et al.Combination of enzastaurin and ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma［J］.J Exp Clin Cancer Res,2019,38(1):86.
［4］ ALIZADEH A A,EISEN M B,DAVIS R E,et al.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling［J］.Nature,2000,403(6769):503-511.
［5］ DAVIES A.Tailoring front-line therapy in diffuse large B-cell lymphoma:who should we treat differently［J］.Hematology Am Soc Hematol Educ Program,2017,2017(1):284-294.
［6］ GUO L,LIN P,XIONG H,et al.Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment［J］.Biochim Biophys Acta Rev Cancer,2018,1869(2):85-96.
［7］ PASQUALUCCI L,DALLA-FAVERA R.Genetics of diffuse large B-cell lymphoma［J］.Blood,2018,131(21):2307-2319.
［8］ CHO K M,KEAM B,HA H,et al.Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP［J］.Korean J Intern Med,2019,34(4):885-893.
［9］ WOYACH J A,BLACHLY J S,ROGERS K A,et al.Acalabrutinib plus obinutuzumab in treatment-naive and relapsed/refractory chronic lymphocytic leukemia［J］.Cancer Discov,2020,10(3):394-405.
［10］ DUARTE D P,LAMONTANARA A J,LA SALA G,et al.Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms［J］.Nat Commun,2020,11(1):2319.
［11］ BARTLETT N L,COSTELLO B A,LAPLANT B R,et al.Single-agent ibrutinib in relapsed or refractory follicular lymphoma:a phase 2 consortium trial［J］.Blood,2018,131(2):182-190.
［12］ BURGER J A,WIESTNER A.Targeting B cell receptor signalling in cancer:preclinical and clinical advances［J］.Nat Rev Cancer,2018,18(3):148-167.
［13］ DOBROVOLSKY D,WANG E S,MORROW S,et al.Bruton tyrosine kinase degradation as a therapeutic strategy for cancer［J］.Blood,2019,133(9):952-961.
［14］ SHANAFELT T D,WANG X V,KAY N E,et al.Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia［J］.N Engl J Med,2019,381(5):432-443.
［15］ 佟丹江.弥漫大B细胞淋巴瘤的流行病学分析［J］.中国现代药物应用,2016(8):46-47.
［16］ GRIMM K E,O′MALLEY D P.Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues［J］.Ann Diagn Pathol,2019,38:6-10.
［17］ CASTILLO J J,CHAVEZ J C,HERNANDEZ-ILIZALITURRI F J,et al.CD20-negative diffuse large B-cell lymphomas:biology and emerging therapeutic options［J］.Expert Rev Hematol,2015,8(3):343-354.
［18］ LI J,ZHAO S,WANG J,et al.CD20-negative diffuse large B cell lymphoma:a comprehensive analysis of 695 cases［J］.Tumour Biol,2016,37(3):3619-3637.
［19］ RUPPERT A S,DIXON J G,SALLES G,et al.International prognostic indices in diffuse large B-cell lymphoma:a comparison of IPI,R-IPI,and NCCN-IPI［J］.Blood,2020,135(23):2041-2048.
［20］ 牛彤.169例弥漫大B细胞淋巴瘤的临床研究［D］.兰州：甘肃中医药大学,2020.
［21］ 宋佳琳,魏小磊,张元坤,等.IPI、NCCN-IPI及年龄调整的IPI评分系统在弥漫大B细胞淋巴瘤患者中的预后价值比较［J］.中华血液学杂志,2018，39（9):739-744.
［22］ LI S,YOUNG K H,MEDEIROS L J.Diffuse large B-cell lymphoma［J］.Pathology,2018,50(1):74-87.
［23］ SALLES G,BARRETT M,FOA R,et al.Rituximab in B-cell hematologic malignancies:a review of 20 years of clinical expe-rience［J］.Adv Ther,2017,34(10):2232-2273.
［24］ IACOBONI G,ZUCCA E,GHIELMINI M,et al.Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL):a critical review［J］.Ann Oncol,2018,29(5):1120-1129.
［25］ 孙梦琪,赵曙,张清媛.CD20阴性的弥漫大B细胞淋巴瘤的研究进展［J］.临床肿瘤学杂志,2017,22(5):461-464.
［26］ REDDY N M,THIEBLEMONT C.Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma:current perspective［J］.Ann Oncol,2017,28(11):2680-2690.
［27］ YAZBECK V,SHAFER D,PERKINS E B,et al.A phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-cell lymphoma［J］.Clin Lymphoma Myeloma Leuk,2018,18(9):569-575.
［28］ GOURD E.New treatment option for relapsed or refractory DLBCL［J］.Lancet Oncol,2019，20（12）:e610.
［29］ 王雪莹,石琳,程志.嵌合抗原受体修饰T细胞治疗血液系统恶性肿瘤研究进展［J］.新乡医学院学报,2019,36(2):111-115.
［30］ CHOW V A,SHADMAN M,GOPAL A K.Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma［J］.Blood,2018,132(8):777-781.
［31］ XU-MONETTE Z Y,ZHOU J,YOUNG K H.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas［J］.Blood,2018,131(1):68-83.
［32］ 胡雷,张瑞,毛露,等.PD-1抑制剂作为治疗非霍奇金淋巴瘤新靶点的疗效展望［J］.医学理论与实践,2020,33(2):209-211.
［33］ GOY A,RAMCHANDREN R,GHOSH N,et al.Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL［J］.Blood,2019,134(13):1024-1036.
［34］ XIA S,LIU X,CAO X,et al.T-cell expression of Bruton′s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia［J］.Cell Mol Immunol,2020，17(10):1042-1052.
［35］ SEILER T,DREYLING M.Bruton′s tyrosine kinase inhibitors in B-cell lymphoma:current experience and future perspectives［J］.Expert Opin Investig Drugs,2017,26(8):909-915.
［36］ TAM C S,TROTMAN J,OPAT S,et al.Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL［J］.Blood,2019,134(11):851-859.
［37］ YOUNG R M,PHELAN J D,WILSON W H,et al.Pathogenic B-cell receptor signaling in lymphoid malignancies:new insights to improve treatment［J］.Immunol Rev,2019,291(1):190-213.
［38］ HERRERA A F,GOY A,MEHTA A,et al.Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma［J］.Am J Hematol,2020,95(1):18-27.
［39］ WANG M L,RULE S,MARTIN P,et al.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma［J］.N Engl J Med,2013,369(6):507-516.
［40］ BERGLOF A,HAMASY A,MEINKE S,et al.Targets for ibrutinib beyond B cell malignancies［J］.Scand J Immunol,2015,82(3):208-217.
［41］ WILSON W H,YOUNG R M,SCHMITZ R,et al.Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma［J］.Nat Med,2015,21(8):922-926.
［42］ MONDELLO P,MIAN M.Frontline treatment of diffuse large B-cell lymphoma:beyond R-CHOP［J］.Hematol Oncol,2019,37(4):333-344.
［43］ WINTER A M,LANDSBURG D J,MATO A R,et al.A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib［J］.Blood,2017,130(14):1676-1679.
［44］ 吴东维.依鲁替尼诱导DLBCL细胞凋亡及克服骨髓基质细胞介导的DLBCL细胞耐药作用机制研究［D］.天津：天津医科大学,2018.
［45］ ADVANI R H,BUGGY J J,SHARMAN J P,et al.Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies［J］.J Clin Oncol,2013,31(1):88-94.
［46］ KHAN Y,O′BRIEN S.Acalabrutinib and its use in treatment of chronic lymphocytic leukemia［J］.Future Oncol,2019,15(6):579-589.
［47］ DAS M.Zanubrutinib in B-cell malignancies［J］.Lancet Oncol,2019,20(9):e470.
［48］ HAVRANEK O,XU J,KOHRER S,et al.Tonic B-cell receptor signaling in diffuse large B-cell lymphoma［J］.Blood,2017,130(8):995-1006.
［49］ SAUTER C S,MATASAR M J,SCHODER H,et al.A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL［J］.Blood,2018,131(16):1805-1808.
［50］ YOUNES A,SEHN L H,JOHNSON P,et al.Randomized phase Ⅲ trial of ibrutinib and rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma［J］.J Clin Oncol,2019,37(15):1285-1295.
［51］ HERRERA A F,GOY A,MEHTA A,et al.Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma［J］.Am J Hematol,2020,95(1):18-27.
［52］ HE Y,LI J,DING N,et al.Combination of enzastaurin and ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma［J］.J Exp Clin Cancer Res,2019,38(1):86.
［53］ 梁碧琦,谭晓虹,孙洁,等.利妥昔单抗与依鲁替尼对弥漫性大B细胞淋巴瘤细胞增殖和凋亡协同作用研究［J］.中华肿瘤防治杂志,2017,24(8):535-539.